Westfield Capital Management Co. LP Cuts Stake in Sanofi (NASDAQ:SNY)

Westfield Capital Management Co. LP lowered its holdings in shares of Sanofi (NASDAQ:SNY) by 6.8% during the 3rd quarter, Holdings Channel.com reports. The firm owned 109,867 shares of the company’s stock after selling 8,037 shares during the quarter. Westfield Capital Management Co. LP’s holdings in Sanofi were worth $6,332,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Northwest Investment Counselors LLC bought a new position in shares of Sanofi during the third quarter valued at about $29,000. POM Investment Strategies LLC purchased a new stake in Sanofi during the 2nd quarter valued at about $25,000. Concord Wealth Partners grew its position in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after acquiring an additional 363 shares during the last quarter. Arrow Financial Corp purchased a new position in Sanofi in the 2nd quarter worth approximately $35,000. Finally, Fortitude Family Office LLC increased its stake in Sanofi by 708.6% in the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after purchasing an additional 659 shares during the period. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Trading Up 0.6 %

SNY opened at $48.28 on Monday. Sanofi has a one year low of $45.22 and a one year high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The business has a 50 day simple moving average of $53.70 and a two-hundred day simple moving average of $52.18. The firm has a market capitalization of $122.53 billion, a price-to-earnings ratio of 24.63, a PEG ratio of 1.22 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. During the same quarter in the prior year, the company earned $2.55 earnings per share. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. Analysts predict that Sanofi will post 4.29 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.